The Leniwand device, combining vibration and cold, reduces pain more effectively than vibration alone during hair transplant injections.
June 2018 in “Dermatologic Surgery”
TrichoSolTM is safe for hair loss treatments with specific ingredient stability for up to 180 days.
2 citations
,
June 2023 in “Clinical Cosmetic and Investigational Dermatology” Using a dexpanthenol ointment after micro-needling speeds up skin healing without affecting benefits.
15 citations
,
August 2002 in “British Journal of Ophthalmology” Intralesional cidofovir might be a viable alternative treatment for certain conditions.
August 2023 in “MPPKI (Media Publikasi Promosi Kesehatan Indonesia) : The Indonesia journal of health promotion” The document's conclusion cannot be provided because the document is not available or cannot be parsed.
4 citations
,
January 2009 in “International journal of trichology” Minoxidil topical foam is a better, less irritating treatment for hair loss.
Combining Minoxidil with topical Dutasteride via microneedling is the most effective and safe treatment for hair loss.
3 citations
,
November 2021 in “Frontiers in medicine” Methotrexate effectively controls eye inflammation in Japanese patients with non-infectious uveitis but requires careful monitoring for side effects.
1 citations
,
March 2011 in “Hospital Pharmacy” Various medications and vaccines can cause serious side effects.
December 2025 in “International Journal of Dermatology” Combining low-dose oral minoxidil with immunomodulators shows promise for treating alopecia areata but needs more research.
April 2026 in “Microsystems & Nanoengineering” HA-gel-dex hydrogels help heal wounds and regenerate tissue effectively.
18 citations
,
March 2006 in “Expert Review of Neurotherapeutics” The document concludes that managing side effects of MS therapies is crucial for treatment success and patient adherence.
42 citations
,
August 2012 in “Psychoneuroendocrinology” Finasteride reduces certain behaviors caused by D1-like receptor agonists but not by D2-like receptor agonists in mice.
9 citations
,
April 2016 in “Australasian journal of dermatology” Combining imiquimod with diphenylcyclopropenone may improve treatment outcomes for alopecia areata patients who don't respond to diphenylcyclopropenone alone.
2 citations
,
January 2021 in “PLANT ARCHIVES” Andrographolide-loaded topical nanocarriers are a safe and effective treatment for psoriasis.
April 2016 in “Journal of The American Academy of Dermatology” Low-cost videomicroscopy may not be reliable for diagnosing hair loss compared to standard videodermatoscopy.
Melatonin can improve treatment and extend remission for certain skin conditions.
1 citations
,
July 2015 in “British Journal of Dermatology” Imiquimod improved skin pigmentation in most patients with xeroderma pigmentosum and may prevent further skin cancer, but some treatments can have side effects.
May 2025 in “Pakistan Armed Forces Medical Journal” Dithranol is more effective than Tacrolimus for hair regrowth in alopecia areata.
The treatment was ineffective in humans.
28 citations
,
September 2014 in “Journal of Veterinary Internal Medicine” VDC-1101 shows potential as a treatment for canine cutaneous T-cell lymphoma.
September 2023 in “bioRxiv (Cold Spring Harbor Laboratory)” Microneedle patches with different pore sizes can effectively deliver drugs and trigger strong immune responses.
September 2017 in “Journal of Investigative Dermatology” RCS-01 is safe and may help rejuvenate aging skin.
16 citations
,
April 2000 in “Journal of Investigative Dermatology” The AVET system effectively delivers genes to human keratinocytes and may help treat skin diseases.
November 2020 in “International journal of pharmaceutical compounding” A stable and simple finasteride suspension was developed that retains over 94.3% of its concentration for up to 90 days and doesn't significantly increase occupational exposure, but safety measures are still advised.
April 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” Most patients experienced mild to moderate skin problems during a trial for a desmoid tumor treatment.
2 citations
,
March 1989 in “International Journal of Dermatology” January 2026 in “Elsevier eBooks”
25 citations
,
July 2024 in “Frontiers in Pharmacology” Rimegepant causes more nausea and skin issues, while ubrogepant causes more muscle issues; personalized treatment is important.